Fecal Calprotectin Levels, C-Reactive Protein Levels, and Partial Mayo Score as Early Predictors of Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Treated With Tofacitinib in a Phase 2 Study

被引:2
作者
Dubinsky, Marla C. [1 ]
Hudesman, David P. [2 ]
Kulisek, Nicole [3 ]
Salese, Leonardo [3 ]
Paulissen, Jerome [4 ]
Su, Chinyu [3 ]
Magro, Fernando [5 ,6 ]
机构
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] New York Univ Langone Hlth, New York, NY USA
[3] Pfizer Inc, Collegeville, PA USA
[4] Syneos Hlth, Morrisville, NC USA
[5] Univ Porto, Porto, Portugal
[6] Ctr Hosp Sao Joao, Porto, Portugal
关键词
D O I
10.14309/01.ajg.0000592828.44710.08
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
823
引用
收藏
页码:S474 / S475
页数:2
相关论文
共 2 条
[1]   Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial [J].
Sandborn, William J. ;
Panes, Julian ;
Zhang, Haiying ;
Yu, Dahong ;
Niezychowski, Wojciech ;
Su, Chinyu .
GASTROENTEROLOGY, 2016, 150 (01) :96-102
[2]   Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis [J].
Sandborn, William J. ;
Ghosh, Subrata ;
Panes, Julian ;
Vranic, Ivana ;
Su, Chinyu ;
Rousell, Samantha ;
Niezychowski, Wojciech .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (07) :616-624